INTRODUCTION

The dynamic and reversible acetylation of protein, catalyzed by lysine acetyltransferases (KATs, also known as HATs) and deacetylases, plays critical roles in a wide range of biological processes including transcriptional regulation, DNA damage repair, signal transduction, stem cell self-renewal, cellular metabolism, and biological rhythm. Lysine acetyltransferases are a highly diverse group of enzymes. Under the action of KATs, the acetyl group from acetyl coenzyme A is co- or posttranslationally attached to either the \( \alpha \)-amino group of the N-terminus or the \( \varepsilon \)-amino group of lysine residues of proteins including both histone and nonhistone
identified which KAT has important roles in cancer cell growth and survival in vitro. Our studies prioritize a subset of KATs for future research focused on understanding the molecular mechanisms and therapeutic potential.

2 | MATERIALS AND METHODS

2.1 | Genomic and clinical data on TCGA and METABRIC cancer samples

Genetic and expression alteration data from 10 967 tumor samples spanning 33 tumor types in The Cancer Genome Atlas (TCGA) Pan-Cancer studies were obtained from the cBioPortal for Cancer Genomics\(^1\) (http://www.cbioportal.org). In the cBioPortal, for each KAT gene was generated by the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm and categorized as copy number level per gene: −2, possible homozygous deletion; −1, heterozygous deletion; 0, diploid; 1, low-level gain; and 2, high-level amplification. The relative expression of an individual gene and the gene's expression distribution in a reference population were analyzed in mRNA expression data. The reference population consists of tumors that are diploid for the gene in question. The Z score represents the number of standard deviations the expression of a gene is from the reference population gene expression. Somatic mutation data were obtained by exome sequencing.\(^1\)\(^9\) Breast cancer subtype and clinicopathologic information were obtained from a previous publication and extracted through cBioPortal.\(^19\) Among the 1084 breast cancer samples, 981 had intrinsic subtype data available, including 36 normal-like, 499 luminal A, 197 luminal B, 78 human epidermal growth factor receptor 2-enriched (HER2+), and 171 basal-like breast cancers.\(^19\)\(^22\)

A detailed description of the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset can be found in the original publication.\(^24\) The CNAs and normalized expression data from the METABRIC database were downloaded with permission from the European Genome-phenome Archive (https://www.ebi.ac.uk/ega) under accession number EGAC000000000005 as well as from the cBioPortal for Cancer Genomics.\(^19\) In the METABRIC dataset, 1974 samples had subtype data available, including 199 normal-like, 718 luminal A, 488 luminal B, 240 HER2+, and 329 basal-like breast cancers.\(^24\)

2.2 | Semiquantitative PCR reactions

To assess gene expression at the mRNA level, RNA was prepared from human breast cancer cell lines and the MCF10A cell line by using an RNeasy Plus Mini Kit (Qiagen).\(^21\) RNA was mixed with qScript cDNA SuperMix (Quanta Biosciences) and then converted to cDNA through an RT reaction. The cDNA was then used for real-time PCR reactions. Primer sets were obtained from Life Technologies. A PUM1 primer set was used as a control. Semiquantitative RT-PCR
was carried out using the FastStart Universal SYBR Green Master (Roche Diagnostics) as described earlier.\textsuperscript{21,22}

### 2.3 | Cell culture and growth assays

The SUM cell lines were obtained from Dr Stephen P. Ethier, and the remaining cell lines were obtained from ATCC and German Collection of Microorganisms and Cell Cultures. All cell lines were tested routinely and authenticated using cell morphology, proliferation rate, a panel of genetic markers, and contamination checks. To determine the effect of NAA10 overexpression on the growth of human breast cancer in vitro, NAA10 expression was knocked down using siRNA in human breast cancer cell lines. The siRNAs were purchased from Sigma-Aldrich. We used a MISSION siRNA Universal Negative Control for the negative control group. For the transfection procedure, cells were seeded in appropriate cell culture plates and maintained overnight under standard conditions. Plate sizes, cell densities, and siRNA quantities were dependent on the cell line and the experimental setup; siRNA was transfected using the MISSION siRNA transfection reagent according to the manufacturer’s protocol (Sigma-Aldrich). Expression levels of NAA10 mRNA and protein in knockdown cells were measured by quantitative (q)RT-PCR and western blot assays 48 and 72 hours after siRNA transfection, respectively. Five days after siRNA transfection, CellTiter-blue cell viability assays (Promega) were undertaken according to the manufacturer’s guideline.

### 2.4 | Immunoblotting and Abs

Immunoblot assays were carried out as previously described.\textsuperscript{21,22} Whole-cell lysates were prepared by scraping cells from the dishes into cold RIPA lysis buffer. Centrifugation protein content was estimated by the Bradford method. A total of 20-50 μg of total cell lysate was resolved by SDS-PAGE and transferred onto a PVDF membrane. Antibodies used for the western blot in the study included anti-NAA10 (1:1000 GTX125971; GeneTex) and anti-β-actin (1:5000 A5441; Sigma-Aldrich).

### 2.5 | Statistical analysis

Statistical analyses were undertaken using R software (http://www.r-project.org) and GraphPad Prism (version 6.03).\textsuperscript{21,22} Statistical significance of the differences in mRNA expression level for each KAT among different subtypes, stages, and grades of breast cancer samples was determined using ANOVA and Welch’s t test as described earlier.\textsuperscript{21,22} Spearman and Pearson correlation tests were used to correlate copy numbers and mRNA levels of each KAT from approximately 10 000 TCGA Pan-Cancer samples together, as well as 20 individual cancer types that contained at least 200 samples. We used the “cor” function in R for computation, specifying which type of test we wanted (Spearman or Pearson). Relationships between KAT mRNA expression and disease-free survival in METABRIC breast cancer were analyzed by equally dividing 1980 samples into high and low expression groups for each KAT based on mRNA expression Z scores. Thus, there were 990 samples each with high or low expression for each KAT gene. A similar statistical method was also used for survival analysis of individual subtypes of METABRIC cancer patients.

### 3 | RESULTS

#### 3.1 | Genomic alterations of KATs across 33 human tumor types

Genetic alterations, including CNA and somatic mutation, are a universal hallmark of cancer.\textsuperscript{25,26} We hypothesized that KATs with recurrent genetic alterations and mRNA dysregulations play important roles in different types of human tumor, and hence serve as diagnostic and therapeutic targets. Based on the current ChromoHub database, the human genome encodes 37 KAT proteins with demonstrated or predicted acetyltransferase activity (Figure S1 and Table S1).\textsuperscript{2,3} We first analyzed CNAs and mutations in 37 KAT genes compiled from 10 967 TCGA samples (Pan-Cancer cohort) across 33 divergent tumor types.\textsuperscript{19,20} These 33 tumor types include 3 lymphatic and hematologic tumors and 30 solid tumors (Table S2). The copy number for each KAT was generated by the copy number analysis algorithm GISTIC and categorized according to copy number level per gene as high-level amplification, low-level gain, diploid, shallow deletion (possibly a heterozygous deletion), and deep deletion (possibly a homozygous deletion). Somatic mutation data were obtained from exome sequencing.\textsuperscript{19,20} We will use the term “alteration” henceforth for gene amplification, deep deletion, and mutations, including missense mutation, gene truncation, and fusion. In the Pan-Cancer cohort, 42% of the tumors contained an alteration in at least 1 of the 37 KAT genes. Among genomic alterations, KAT6A (3.18%) and NAA10 (1.78%) were the most frequently amplified, and ESCO2 (2.68%) and ELP3 (2.64%) were most frequently deeply deleted (Figure 1A, B). In mutations, 2 pairs of homologs CREBBP (4.65%) and EP300 (4.22%), and TAF1 (3.46%) and TAF1L (4.48%) were the most mutated KATs in the TCGA Pan-Cancer cohort (Figure 1C).

There is considerable variation in the KAT genes altered across different tumor types. We found that 3 KAT genes were amplified in more than 10% of individual TCGA solid tumors; KAT6A was amplified in 17.86% of uterine carcinosarcoma, BRD4 was amplified in 12.06% of ovarian cancer (OV), and ESCO1 was amplified in 10.38% of pancreatic cancer samples (Figure 1A and Table S3). The highest percentages of deep deletion were ESKO2 in prostate cancer (6.95%) and OV (6.47%) samples (Figure 1B and Table S4). Seven KAT genes (CREBBP, EP300, KAT6A, TAF1, TAF1L, MCM3AP, and CIITA) had mutation frequencies greater than 10% in at least 1 tumor type (Figure 1C and Table S5). Notably, CREBBP was mutated in more than 10% of 4 tumor types: bladder cancer (BLCA, 13.41%), uterine corpus endometrial...
cancer (UCEC, 12.77%), diffuse large B-cell lymphoma (12.20%), and melanoma (SKCM, 1.205%). The highest frequency of mutation in TAF1, EP300, and TAF1L is in UCEC (20.12%), BLCA (15.85%), and SKCM (15.45%), respectively. Taken together, among 37 KATs, several KAT genes, including KAT6A, NAA10, CREBBP/EP300, TAF1/L, TAF1L, ESCO2, and ELP1 had relatively higher frequencies of genetic alterations in a spectrum of human tumors.

3.2 | Mutation profiling of CREBBP/EP300 and TAF1/TAF1L

The CBP/p300 (KAT3) subfamily of KATs is composed of 2 homologous enzymes, CREBBP and EP300, both containing a well-conserved acetyltransferase domain and a number of protein interaction domains (e.g., bromodomain and plant homeodomain) that facilitate binding with over 400 proteins. 27-29 CREBBP and EP300 are key transcriptional coactivators that are essential for a multitude of cellular processes. 27 Both CREBBP and EP300 were highly mutated (more than 4%) in TCGA Pan-Cancer samples. In 10,436 TCGA samples with mutation data, there are 629 CREBBP mutations, including 451 missense, 148 truncating, 8 in-frame, and 22 fusion mutations. The most mutated site of CREBBP was R1446 (15 samples with missense mutation) which is located at the KAT enzymatic domain (Figure 2). For EP300, there are 556 mutations, including 378 missense, 159 truncating, 5 in-frame, and 14 fusion mutations. The most mutated residue of EP300 was D1399, which also is located at the KAT enzymatic domain (Figure 2).

The TAF1 gene encodes the largest subunit of the transcription factor II D complex, which promotes transcriptional initiation and activation. 30 The TAF1 homologue TAF1L has 95% amino acid identity with TAF1. 31 In TCGA Pan-Cancer, there are 477 TAF1 mutations, including 418 missense, 54 truncating, 4 in-frame, and 1 fusion mutations. R869, which is located at the putative histone acetyltransferase domain of TAF1, had the highest frequency (9 mutations) of mutations (Figure 2). For TAF1L, there are 625 mutations, 565 missense, 58 truncating, 1 in-frame, and 1 fusion mutations. R658, R1205, and R1252 have mostly missense mutations (Figure 2). Together, 4 KAT genes (CREBBP, EP300, TAF1, and TAF1L) had higher frequencies of somatic mutation, and enriched mutation sites likely have an effect on their KAT activities.

3.3 | Copy number and expression profiling of KATs in different subtypes of breast cancer

Breast cancer is the most common cancer and one of the leading causes of cancer death among women. Using gene expression profiling, breast cancer has been classified into 5 intrinsic subtypes with distinct risks and underlying biology; these 5 subtypes are luminal A, luminal B, HER2+, basal-like, and normal-like breast cancers. 23,32 One of the KATs, MAPT, is in the PAM50 (prediction analysis for microarray
KAT6A genes including greater than 0.5) in basal-like compared with luminal subtypes, and 11 P also significantly higher expressed (>0.3) in luminal compared with basal-like subtypes (Figure 3B and Table S10).

To validate our findings from TCGA breast cancer dataset regarding KAT genetic alterations, we undertook an independent analysis using the METABRIC dataset, which contains 2509 breast cancer samples with long-term clinical follow-up data. We found that KAT6A had the highest frequency (10.81%) of high-level amplification in the METABRIC breast cancer samples (Table S9). Among 37 KAT genes, 3 genes, EP300, TAF1, and NCOA3, had been selected for the mutation analysis with the frequencies of 2.75%, 2.07%, and 1.63%, respectively, in METABRIC breast cancer samples. For mRNA expression, data for 33 KATs were available (mRNA data of EP300, TAF1, and NCOA3 were not available) in the METABRIC data set. Again, we found that 3 KATs (NAA10, ACAT2, and DLAT) had significantly higher expression (P < .05, mean Z score difference greater than 0.5), whereas 5 KATs (MAPT, CREBBP, EP300, KAT6B, KAT7, and NAA60) were underexpressed in METABRIC basal-like subtypes compared with luminal subtypes (Figure 3B and Table S10).

3.4 | Association of KAT gene expression with clinical features and survival of breast cancer patients

We next investigated the clinical relevance of KAT expressions in the METABRIC cohort, as the METABRIC breast cancers have long-term clinical follow-up data. We first examined expression levels of each KAT gene at different grades of METABRIC breast cancer samples. The means of Z score and P value for each KAT gene across grades 1-3 are shown in Table S11. We found that 3 genes, NAA10, ACAT2, and NCOA3 were significantly overexpressed in higher-grade breast cancers (t test: grade 3 vs 1 + 2; P < .001 and means difference greater than 0.4; Figure 3C and Table S11). The Nottingham prognostic index (NPI), a clinicopathologic classification system based on tumor size, histological grade, and lymph node status that is widely used in Europe for breast cancer prognostication, was also available in the METABRIC cohort. Thus, we compared expression levels of KATs between patients with high NPI (greater than 3.4) vs those with low NPI (3.4 or less). As shown
in Figure 3D and Table S11, 3 KATs, NAA10, ACAT2, and NCOA3, were significantly overexpressed, whereas ELP3 and MAPT were underexpressed in samples with higher NPI (P < .001 and means Z score difference greater than 0.4) compared with that in lower NPI samples.\(^{35}\) Next, we analyzed the relationship between KAT mRNA expression and disease-free survival of METABRIC breast cancer patients. We found that higher mRNA levels of 4 KATs (ACAT2, BRD4, NAA10, and NCOA3) and lower expression of 5 KATs (MAPT, ACAT1, ELP3, KAT2A, and KAT8) were significantly associated with shorter disease-free survival in METABRIC breast cancer patients (P < .005) (Figures 4A and S3, and Table S12).\(^{35}\)

We also undertook survival analysis of KATs in different subtypes of breast cancer. As shown in Table S12, we found that higher expression of BRD4 was significantly associated with shorter disease-free survival in basal-like and luminal B subtypes, whereas lower expression of MAPT and ACAT1 was significantly with shorter disease-free survival in luminal A patients (P < .05). In summary, we found that three KATs, NAA10, ACAT2, and BRD4, were highly expressed in the aggressive basal-like subtype, and NCOA3 was highly expressed in luminal B subtype, and several KATs (eg BRD4 and NAA10) were significantly associated with tumor grade and disease-free survival of breast cancers.

### 3.5 Potential role of NAA10 in breast cancer proliferation

The availability of multiple datasets comprising genome-scale RNAi viability screens in hundreds of diverse cancer cell lines presents new opportunities for understanding cancer vulnerabilities.\(^{36,37}\)
To determine how endogenous KATs contribute to growth and viability of tumor cells, we analyzed a genome-wide loss-of-function shRNA screen in 712 tumor lines (https://depmap.org/portal/).36,38,39 We ranked average dependency (DEMETER2) scores of all 37 KATs and revealed that 6 of them, notably MCM3AP, NAA10 and BRD4, have average DEMETER2 scores of less than −0.5 (lower score means more dependency on target) (Figure 4B).40 Given that NAA10 was overexpressed in advanced stage, higher grade, and basal-like breast cancer, we undertook a more detailed analysis of NAA10 shRNA screen data in breast cancer cell lines. Among 80 breast cancer lines, 63 lines have DEMETER2 scores of less than −0.5, and among them, 10 lines have scores of less than −1.0 (Table S13).

Next, we carried out qRT-PCR and western blot assays to measure NAA10 in 22 breast cancer cell lines. Compared with MCF10A, an immortalized but nontumorigenic breast epithelial cell line, mRNA levels of NAA10 were highly expressed in 13 lines, particularly the basal-like subtype lines including SUM149, MDA-MB-468, and SUM1315 (Figure 5A). Expression levels of the NAA10 protein were also higher in basal-like breast cancer lines (Figure 5B). To confirm the results of genome-wide RNAi screens in cancer cell lines, we examined the effects of knocking down NAA10 in SUM149, MDA-MB-468, and SUM1315 basal-like breast cancer lines. We obtained 3 siRNAs targeting different regions of NAA10 gene. Quantitative RT-PCR and western blot assays revealed that 2 siRNAs significantly decreased the expression of NAA10 at mRNA and protein levels (Figures 5C and S4). As shown in Figure 5C, NAA10 knockdown dramatically slowed SUM149 cell growth to approximately 40% of the growth of the nonsilenced control. NAA10 knockdown also modularly, but statistically significantly, slowed MDA-MB-468 and SUM1315 growth (Figure 5C). Our genomic, clinical, and in vitro cellular data suggest that NAA10 has a potential role in promoting breast cancer growth and progression.
Here, we describe the genomic and functional analysis of 37 KATs in a large cohort of human cancer primary samples and cell lines. Our Pan-Cancer analysis showed that several KAT genes, including KAT6A, NAA10, CREBBP/EP300, and TAF1/TAF1L have relatively higher frequencies of genetic alterations in various human cancers. Next, we undertook integrated genomic and transcriptomic analyses of KAT genes in breast cancer with different molecular subtypes and clinicopathologic features. We identified that a subset of KAT genes, notably KAT6A and NAA10, are commonly amplified and overexpressed in breast cancer. Different subtypes of breast cancer had different patterns of copy number and expression of each KAT. Importantly, we found that 3 KATs, NAA10, ACAT2, and BRD4, were highly expressed in the aggressive basal-like subtype, and their expression was significantly associated with disease-free survival. Furthermore, we found that knockdown of NAA10 inhibits basal-like breast cancer growth, suggesting NAA10 has oncogenic potential in breast cancer.

Among 37 KATs, the KAT6A gene (located at 8p11.21) had the highest frequency of amplification in both TCGA Pan-Caner and METABRIC breast cohorts. Notably, more than 5% of breast, uterine, lung squamous, esophageal, and bladder cancers have KAT6A amplification. These data agree with and consolidate prior reports on the genetic alterations and oncogenic potentials of KAT6A in human cancer. For example, Turner-Ivey et al suggested that KAT6A is a candidate oncogene in luminal breast cancer. Furthermore, Yu et al found that KAT6A activates ERα promoter through its histone acetyltransferase function. In this study, we also found that KAT6A was highly amplified and overexpressed in a subset of ER-, basal-like breast cancers. Very recently, Baell and colleagues identified novel competitive KAT6A inhibitors, WM-8014 and WM-1119, which induce cell cycle
exit and senescence and are effective in preventing the progression of lymphoma in mice.\textsuperscript{45} It will be interesting to test KAT6A inhibitors in human cancer models with KAT6A amplification in the future.

**CREBBP** and **EP300** (CBP/p300) are the most mutated KATs in human cancer. It is possible that compensatory mechanisms exist among different KATs in different cell types and functional states. However, previous studies on KAT-null and heterozygous mice have revealed highly specific functions of individual enzymes in development, physiology, and disease.\textsuperscript{5,6,46} Studies using CBP/p300 conditional knockout mice reveal a distinct role for CREBBP and EP300 in defined cell lineages.\textsuperscript{47} Many studies indicated that CBP/p300 functions as tumor suppressors.\textsuperscript{27} Furthermore, CBP/p300 could contribute to DNA repair through histone acetylation and facilitate the recruitment of DNA repair factors to the site of damage.\textsuperscript{48} Our finding, together with others, indicate that the KAT domains of CREBBP and EP300 are hotspots for mutation in human cancer, suggesting the critical roles of KAT function of CREBBP/EP300 in regulating tumor growth and progression.\textsuperscript{27}

Genome-scale shRNA viability screens in human cancer cell lines revealed that, among KATs, MCM3AP, NAA10, and BRD4 have the strongest preferential dependency (Figure 4B). The MCM3AP gene is mutated in 2.36% of TCGA samples, with the highest frequency of mutation (10.06%) in UCEC. The majority of MCM3AP mutations in UCEC tumor were missense. The MCM3AP acetylates MCM3, a highly conserved minichromosome maintenance protein, which is involved in the initiation of genome replication.\textsuperscript{49} Interestingly, 1 UCEC line, called EN, with the MCM3AP mutation has the lowest DEMETER2 score in genome-scale shRNA viability screens of human cancer cell lines (https://depmap.org/portal/). Therefore, it is worth investigating the functional roles of MCM3AP mutation in human cancer, particularly UCEC, and whether it is a novel therapeutic target for UCEC in the future. The functional roles of BRD4 in cancer have been intensively studied; BRD4 plays critical roles in superenhancer organization and oncogene expression regulation.\textsuperscript{50} It was recently reported that BRD4 has intrinsic acetyltransferase activity, although the functional significance of this activity to the function of BRD4 remains to be further investigated.\textsuperscript{51} Nevertheless, BRD4 is currently regarded as one of the most promising new drug targets for both hematological and solid tumors.\textsuperscript{50,52}

N-terminal acetylation impacts the modulations of protein-protein interactions, protein subcellular targeting, folding, stabilization, and degradation.\textsuperscript{7} NAA10 is the catalytic subunit of the N-terminal acetyltransferase NatA complex, which includes NAA10, NAA15, and NAA50.\textsuperscript{7} N-terminal acetylation activity by NAA10 was found to relate strongly to human genetic disease, notably Ogdens syndrome.\textsuperscript{13,14} Studies revealed that Naa10-null mice display partial embryonic lethality, growth retardation, brain disorders, and maternal effect lethality.\textsuperscript{53} In addition, NAA10 can act independently to posttranslationally acetylate a distinct set of substrates, including histone and actin.\textsuperscript{7} Previous studies also showed that NAA10 regulates cell proliferation and cancer formation, DNA damage response, hypoxia, bone formation, and neuronal development in enzymatic activity-dependent and -independent manners.\textsuperscript{54} Our functional study revealed that NAA10 is critical for cancer cell growth and survival, particularly aggressive, basal-like breast cancer. It is important to deeply investigate NAA10 function in different subtypes of breast cancer by overexpressing NAA10 in model cells in the future.

In summary, we undertook a large-scale genomic analysis of 37 KATs in human cancer, focusing on breast cancer. We found that KAT6A and NAA10 were the most commonly amplified and CREBBP/EP300 and TAF1/TAF1L were most often mutated in a spectrum of human cancers. Integrated genomic, transcriptomic, and clinicopathologic data in breast cancers revealed that several KATs, including NAA10, ACAT2, and BRD4, were significantly associated with aggressiveness and poor prognosis of patients. Loss-of-function analysis revealed that NAA10 had important roles in promoting cancer cell growth and survival. Our findings provide a strong foundation for further mechanistic research and for developing therapies that target NAA10 or other KATs in human cancer. Given that many cellular factors can be regulated by KATs, and KATs act in a highly context-specific and cell type-dependent manner, care is required when choosing KAT inhibitors against a specific type of cancer.

**ACKNOWLEDGMENTS**

This work was partially supported by grants from the Department of Defense (DoD) Breast Cancer Program BC161536, DoD Prostate Cancer Program PC130259, and the DMC Foundation to Dr Zeng-Quan Yang. We thank Dr Stephen P. Ethier for providing the SUM breast cancer cell lines. We thank Qianhui Huang for technical contributions, and Madison Bonahoom for proofreading.

**DISCLOSURE**

The authors have no conflict of interest.

**ORCID**

Zeng-Quan Yang https://orcid.org/0000-0002-3658-0081

**REFERENCES**

1. Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. *Biochim Biophys Acta*. 2019;20:7-23.
2. Sheikh BN, Akhtar A. The many lives of KATs - detectors, integrators and modulators of the cellular environment. *Nat Rev Genet*. 2019;20:7-23.
3. Liu L, Zhen XT, Denton E, Marsden BD, Schapira M. ChromoHub: a data hub for navigators of chromatin-mediated signalling. *Bioinformatics*. 2012;28:2205-2206.
4. Hirsh CL, Wrana JL, Dent SYR. KATapulting toward pluripotency and cancer. *J Mol Biol*. 2017;429:1958-1977.
5. Trisciuoglio D, Di Martile M, Del Bufalo D. Emerging role of histone acetyltransferase in stem cells and cancer. *Stem Cells Int*. 2018;2018:8908751.
6. Aksnes H, Drazic A, Marie M, Arnesen T. First things first: vital protein marks by N-terminal acetyltransferases. *Trends Biochem Sci*. 2016;41:746-760.
7. Aksnes H, Ree R, Arnesen T. Co-translational, Post-translational, and Non-catalytic Roles of N-Terminal Acetyltransferases. *Mol Cell*. 2019;73:1097-1114.
8. Di Martile M, Del Bufalo D, Trisciuoglio D. The multifaceted role of lysine acetylation in cancer; prognostic biomarker and therapeutic target. *Oncotarget*. 2016;7:55789-55810.
9. Hu Z, Zhou J, Jiang J, et al. Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nat Commun. 2019;10:733.

10. Korzus E. Rubinstein-taybi syndrome and epigenetic alterations. Adv Exp Med Biol. 2017;978:39-62.

11. Roelfsema JH, Peters DJ. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med. 2007;9:1-16.

12. Tham E, Lindstrand A, Santani A, et al. Dominant mutations in KAT6A cause intellectual disability with recognizable syndromic features. Am J Hum Genet. 2015;96:507-513.

13. Rope AF, Wang K, Evjenth R, et al. Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am J Hum Genet. 2011;89:28-43.

14. Dorfel MJ, Lyon GJ. The biological functions of Naa10 - From amino-terminal acetylation to human disease. Gene. 2015;567:103-131.

15. Yang XJ. MOZ and MORF acetyltransferases: Moleculear interaction, animal development and human disease. Biochim Biophys Acta. 2015;1853:1818-1826.

16. Broyer J, Stanton VP Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14:33-41.

17. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134-1140.

18. Rohira AD, Lonard DM. Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Biochim Pharmacol. 2017;140:1-7.

19. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404.

20. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:p11.

21. Jiang Y, Liu L, Shan W, Yang ZQ. An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer. Mol Oncol. 2016;10:292-302.

22. Liu H, Liu L, Holowatyj A, Jiang Y, Yang ZQ. Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. Mol Carcinogene. 2016;55:977-990.

23. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.

24. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-352.

25. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899-905.

26. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127-1133.

27. Attar N, Kurdistan SK. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harb Perspect Med. 2017;7(3):a026534.

28. Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. Chem Rev. 2015;115:2419-2452.

29. Hu Y, Jiang Y, Liu L, et al. Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. Oncotarget. 2017;8:13099-13115.

30. Filipakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214-231.

31. Wang PJ, Page DC. Functional substitution for TAFII250 by a retrofused homolog that is expressed in human spermatogenesis. Human Mol Genet. 2002;11:2341-2346.

32. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.

33. Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.

34. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207-219.

35. Manning M, Jiang Y, Wang R, et al. Pan-cancer analysis of RNA methyltransferases identifies FTSJ3 as a potential regulator of breast cancer progression. RNA Biol. 2020;17(4):474-486.

36. Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell. 2017;170:564-576.e16.

37. McDonald ER 3rd, de Weck A, Schlabach MR, et al. Project DRIVE: A compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell. 2017:170: 577-592.e10.

38. Marcottare S, Sayad A, Brown KR, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell. 2016;164:293-309.

39. Meyers RM, Bryan JG, McFarland JM, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779-1784.

40. McFarland JM, Ho ZV, Kugener G, et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018;9:4610.

41. Turner-Ivey B, Guest ST, Irish JC, et al. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia. 2014;16:644-655.

42. Huang F, Abmayr SM, Workman JL. Regulation of KAT6 acetyltransferases and their roles in cell cycle progression, stem cell maintenance, and human disease. Mol Cell Biol. 2016;36:1900-1907.

43. Yu L, Liang Y, Cao X, et al. Identification of MYST3 as a novel epigenetic activator of ER alpha frequently amplified in breast cancer. Oncogene. 2017;36:2910-2918.

44. Yu L, Liang Y, Cao X, et al. Identification of MYST3 as a novel epigenetic activator of ERalpha frequently amplified in breast cancer. Oncogene. 2017;36:2910-2918.

45. Baell JB, Leaver DJ, Herrmans SJ, et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature. 2018;560:253-257.

46. Yamauchi T, Yamauchi J, Kuwata T, et al. Distinct but overlapping roles of histone acetylase PCAF and of the closely related PCAF-B/GCN5 in mouse embryogenesis. Proc Natl Acad Sci U S A. 2000;97:11303-11306.

47. Kasper LH, Lerach S, Wang J, Wu S, Jeevan T, Brindle PK. CBP/p300 double null cells reveal essential roles of the CBP transactivation domain. EMBO J. 2010;29:3660-3672.

48. Dutto I, Scalerac C, Prosperi E, CREBBP and p300 lysine acetyltransferases in the DNA damage response. Cell Mol Life Sci. 2018;75:1325-1338.

49. Takei Y, Swietlik M, Tanoue A, Tsujimoto G, Kouzarides T, Laskey R. MCM3AP, a novel acetyltransferase that acetylates replication protein MCM3. EMBO Rep. 2001;2:119-123.

50. Donati B, Lorenzini E, Ciarrocchi A, BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164.

51. Devahah BN, Case-Borden C, Geggone A, et al. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. Nat Struct Mol Biol. 2016;23:540-548.

52. Shu S, Polyak K. BET bromodomain proteins as cancer therapeutic targets. Cold Spring Harbor Symp Quantit Biol. 2016;81:123-129.
53. Lee CC, Peng SH, Shen L, et al. The Role of N-alpha-acetyltransferase 10 Protein in DNA Methylation and Genomic Imprinting. Mol Cell. 2017;68:89-103.e7.

54. Wild J, Schmiedel BJ, Maurer A, et al. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia. 2015;29:1676-1683.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Jiang Y, Guo X, Liu L, et al. Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features. Cancer Sci. 2020;111:1829–1839. https://doi.org/10.1111/cas.14385